Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Saussele

Showing results (11-20 of 32) with videos related to

Pageof 4
Sort By:
Leukemia|November 9, 2000
Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probesS Saussele, A Weisser, M C Müller, et al.
Leukemia|November 11, 1999
Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCRM Emig, S Saussele, H Wittor, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2018
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upA Hochhaus, S Saussele, G Rosti, et al.
Leukemia|September 30, 2015
Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemiaM Pfirrmann, M Baccarani, S Saussele, et al.
Leukemia|September 12, 2008
Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in GermanyM Rohrbacher, U Berger, A Hochhaus, et al.
British Journal of Cancer|July 9, 2004
Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trialR-D Hofheinz, J T Hartmann, A Willer, et al.
Leukemia|June 24, 2000
Detection and quantification of residual disease in chronic myelogenous leukemiaA Hochhaus, A Weisser, P La Rosée, et al.
Leukemia|January 30, 2014
MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failureM Agrawal, B Hanfstein, P Erben, et al.
Blood|December 23, 1999
Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study GroupA Hochhaus, A Reiter, S Saussele, et al.
Leukemia|February 26, 2015
Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemiaA Burchert, S Saussele, E Eigendorff, et al.
Pageof 4

Showing results (11-20 of 32) with videos related to

Sort By:
Pageof 4
Leukemia|November 9, 2000
Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probesS Saussele, A Weisser, M C Müller, et al.
Leukemia|November 11, 1999
Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real time quantitative RT-PCRM Emig, S Saussele, H Wittor, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2018
Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upA Hochhaus, S Saussele, G Rosti, et al.
Leukemia|September 30, 2015
Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemiaM Pfirrmann, M Baccarani, S Saussele, et al.
Leukemia|September 12, 2008
Clinical trials underestimate the age of chronic myeloid leukemia (CML) patients. Incidence and median age of Ph/BCR-ABL-positive CML and other chronic myeloproliferative disorders in a representative area in GermanyM Rohrbacher, U Berger, A Hochhaus, et al.
British Journal of Cancer|July 9, 2004
Capecitabine in combination with mitomycin C in patients with gastrointestinal cancer: results of an extended multicentre phase-I trialR-D Hofheinz, J T Hartmann, A Willer, et al.
Leukemia|June 24, 2000
Detection and quantification of residual disease in chronic myelogenous leukemiaA Hochhaus, A Weisser, P La Rosée, et al.
Leukemia|January 30, 2014
MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failureM Agrawal, B Hanfstein, P Erben, et al.
Blood|December 23, 1999
Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study GroupA Hochhaus, A Reiter, S Saussele, et al.
Leukemia|February 26, 2015
Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemiaA Burchert, S Saussele, E Eigendorff, et al.
Pageof 4